Research study of a currently marketed medication for Alzheimer’s Disease.

Study Description

A phase 4, randomized, parallel group, double-blind, multicenter study comparing the effects of 2 doses of an investigational medication on activities of daily living and cognition in subjects with severe Alzheimer’s Disease.

Length of study: Approximately 6 months.

Number of office visits: Up to 6 visits.

At no cost, qualified participants receive:

• Study-related memory evaluation by a Board-Certified Geriatric Psychiatrist
• MRI scan and study-related diagnostic and laboratory evaluations
• Study medication
• Reimbursement for time and travel for patient and caregiver

Study inclusion/exclusion criteria

This study is only available if the following apply to the potential participant.

• Has significant severe memory impairment
• Is at least 50 years old
• Is in stable medical health
• Does not live in a skilled nursing facility
• Has a reliable caregiver who can accompany the patient

[Home] [For Patients] [Studies] [FAQ] [Sponsor Overview] [Contact Us]